Biogen Inc. (Nasdaq: BIIB) will pay a cash fee of $1.25 billion to Forward Pharma A/S (Nasdaq: FWP) as part of a license agreement and will pay royalties of up to 10-20% of net sales of Biogen products approved for the treatment of multiple sclerosis that are covered by a Forward patent. Shares of Forward Pharma leaped $8.85 to close at $27.20 while Biogen stock fell $1.64 to close at $283.11.
